Sotrovimab in SARS-COV-2 chronic hemodialysis patients in the Omicron era. Is intradialytic administration feasible? Report of 4 cases

Emanuele Mambelli1 · Lorenzo Gasperoni1 · Laura Maldini1 · Carlo Biagetti2 · Angelo Rigotti1

Received: 1 May 2022 / Accepted: 21 August 2022 / Published online: 13 September 2022
© The Author(s) under exclusive licence to Italian Society of Nephrology 2022

Abstract
Chronic hemodialysis patients are at high risk of morbidity and mortality in case of SARS-CoV-2 infection and they may need to be treated with monoclonal antibodies, either because they have not been vaccinated, or because they have a low anti spike antibody titer. Administration of Sotrovimab has recently been proposed for hemodialysis patients, but data are on the results lacking. We report on four cases of chronic dialysis patients who received Sotrovimab during intermittent dialysis sessions. In our series, no adverse reactions were recorded; intradialytic administration resulted safe and allowed an adequate observation time without prolonging hospital stay in chronic hemodialysis outpatients.

Keywords Sotrovimab · SARS-CoV-2 · Hemodialysis · COVID-19

Introduction
Since dialysis patients are at higher risk for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-related morbidity and mortality [1, 2], they have been included among the high risk categories eligible for monoclonal antibody therapy, which demonstrated a reduction of hospitalization rates and mortality [3, 4].

Sotrovimab, formerly known as VIR-7831, is an engineered human monoclonal antibody derived from the parent antibody S309 identified in 2003 SARS-CoV survivors [5].

The prespecified interim analysis of the COMET-ICE trial demonstrated the efficacy of Sotrovimab in reducing the risk of disease progression in non-hospitalized COVID-19 patients with risk factors for severe disease. Although chronic kidney disease was among the risk factors that led to Sotrovimab administration, few of these patients were enrolled and none of them was on chronic dialysis treatment [6].

Sotrovimab retained protection against the Omicron BA.1 variant of concern (VOC), but lost efficacy against the Omicron BA.2 VOC. Thus, once BA.2 spread throughout our territory, the Italian Medicines Agency (AIFA) blocked its use [7].

Alternatively, a short course of the antiviral remdesivir among non-hospitalized patients who were at high risk for Covid-19 progression demonstrated an 87% lower risk of hospitalization or death than placebo [8].

Unfortunately, patients with severe acute kidney injury and end stage kidney disease (ESKD) were excluded from remdesivir trials and although compassionate remdesivir use in dialysis patients was reported to be safe [9], its administration is not recommended in patients with eGFR less than 30 ml per minute [10].

In addition, nirmatrelvir plus ritonavir (paxlovid) demonstrated efficacy in reducing both hospitalization and mortality among non-hospitalized adults with mild-to-moderate COVID-19 who were at high risk for progression to severe COVID-19, but dialysis patients were excluded; given theoretical concerns about drug accumulation and safety, the drug is not recommended for those with eGFR < 30 ml per minute [11, 12]. Nonetheless, a small case series of 15 dialysis patients with COVID-19 treated with lower doses of nirmatrelvir/ritonavir reported rapid symptom resolution with no adverse events [13].
We report a case series of four SARS-CoV-2 chronic hemodialysis patients, all of whom were outpatients, who underwent intradialytic Sotrovimab administration. Infection recovery was defined as a negative nasopharyngeal swab after at least three days without symptoms.

The cases

Pt#1

A 46-year-old male with ESKD due to hypertensive nephropathy was on twice weekly hemodialysis through a proximal arteriovenous fistula. His urinary output and hemodialysis Kt/V were 1500 ml/day and 1.47, respectively. He was not vaccinated for SARS-COV-2. Nasopharyngeal swab was performed because of fever while neither cough nor respiratory failure were present. Symptoms started on day 0 and sotrovimab 500 mg was administered on day 5 during the dialysis session. No adverse reactions were recorded. He experienced rapid clinical improvement with infection recovery after 12 days.

Pt#2

An 87-year-old male with ESKD due to hypertensive nephropathy was on twice weekly hemodialysis through a jugular tunneled central venous catheter. His hemodialysis Kt/V was 1.25 and urinary output was 1700 ml/day. Comorbidities included chronic heart failure, pace-maker for atrio-ventricular block and hypertension. He received 3 doses of the anti-SARS-COV-2 mRNA vaccine, and his anti spike IgG titer at diagnosis was 1410 BAU/mL. The only symptom was cough. The patient was tested on day 0 and received sotrovimab 500 mg on day 3 during the dialysis session. No adverse reactions were recorded. Symptoms gradually improved and he recovered from infection after 14 days.

Pt#3

A 92-year-old male with ESKD was on hemodialysis thrice weekly through a distal arterio venous fistula. Comorbidities included hypertension, ulcerative colitis and psoriasis. He received 3 doses of anti-SARS-COV-2 mRNA vaccine and his antibody titer was > 2080 BAU/mL at the time of infection. He experienced mild fever and cough with no respiratory failure. Symptoms started on day 0 and sotrovimab 500 mg was administered on day 4 during the dialysis session. No adverse reactions were recorded. Symptoms resolved quickly and he recovered from infection after 12 days.

Pt#4

A 61-year-old female with ESKD due to relapsing renal stones was on hemodialysis thrice weekly through a jugular tunneled central venous catheter. Comorbidities included fibromyalgia and deep vein thrombosis on warfarin treatment. She was not vaccinated for SARS-COV-2. Her symptoms were fever and cough without respiratory failure. Symptoms started on day 0 and Sotrovimab 500 mg was administered on day 5 during the dialysis session. No adverse reactions were recorded. Symptoms gradually improved and she recovered from infection after 11 days.

Intradialytic Sotrovimab administration in Chronic Hemodialysis SARS-COV-2 outpatients

Four adult chronic hemodialysis outpatients [median age 74 years (min 46, max 92); 1 female] tested positive for SARS-COV-2 in the Dialysis Unit of the Infermi Hospital (Rimini, Italy). Patients were diagnosed from 6th January to 17th February 2022 by nasopharyngeal swab for SARS-CoV-2 nucleic acid, using reverse transcription polymerase chain reaction (RT-PCR). The viral load was not evaluated since it is not routinely available in our hospital. Two patients were unvaccinated. The two vaccinated patients had received two doses + a booster dose of the Spikevax (ex COVID-19 Moderna mRNA-1273) Vaccine. They had mild symptoms, the most common being fever and cough (Table 1). Anti-protein S antibody was measured soon after the diagnosis of SARS-COV-2 infection in three of the four patients. One patient was given the indication to treatment without the need for the Anti-Spike dosage since he was unvaccinated and young.

Although the SARS-CoV-2 variant was not assessed, Omicron BA1 accounted for more than 95% of cases in our district in that period [14]. Infectious disease clinicians gave the indication to therapy. Sotrovimab 500 mg was diluted in 100 ml of physiological saline solution and administrated over 30 min during the second hour of a routine, planned hemodialysis session. No treatment was given other than Sotrovimab and dialysis.

No adverse reactions were recorded. All subjects were managed as outpatients until infection recovery and none of them experienced symptom worsening or respiratory failure.

Clinical, laboratory and dialysis features are shown in Table 1. Median Charlson Comorbidity Index was 4.5 (min
2, max 7). The median time between symptom onset and Sotrovimab administration was 4.5 days (min 3; max 5). All patients recovered from infection and symptoms.

**Discussion**

To our knowledge this is the first report of intradialytic Sotrovimab administration in non-hospitalized chronic hemodialysis patients.

Sotrovimab is a large protein (human immunoglobulin IgG1-kappa) with a molecular weight of 149 KDa, so it is not expected to be dialyzed.

We administered the drug during the second hour of the hemodialysis session in all four outpatients.

|                | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
|----------------|-----------|-----------|-----------|-----------|
| Age (years)/sex| 46/male   | 87/male   | 92/male   | 61/female |
| Dialysis vintage (months) | 17       | 3        | 60       | 40       |
| Charlson score  | 2        | 7        | 6        | 5        |
| Vascular access | Proximal AVF | Tunneled CVC | Distal AVF | Tunneled CVC |
| Comorbidities   | Hypertension | PM for AVB, CHF, Hypertension | UC, psoriasis, Hypertension | DVT in VKA, fibromyalgia |
| SARS-COV-2 vaccination | None | 3 doses | 3 doses | None |
| Previous SARS-COV-2 infection | None | None | Yes, 21 months before re-infection | None |
| Dialysis technique | HD | HD | OLHDF | HD |
| Dialysis membrane | Polysulfone | Polysulfone | Polysulfone | Polysulfone |
| Dialysis schedule | Twice weekly | Twice weekly | Thrice weekly | Thrice weekly |
| Dialysis sessions performed during infection period (n.) | 4 | 5 | 5 | 5 |
| Days between symptoms onset and sotrovimab administration | 5 | 3 | 4 | 5 |
| Qb, mL/min, median (min;max) | 300 (250;300) | 300 (250;300) | 300 (250;300) | 280 (280;300) |
| Convective volume L, median (min–max) | NA | NA | 14 (14;18) | NA |
| Fluid removal per session L, median (min–max) | 1.6 (0.7 – 2) | 2.3 (1.6;3.3) | 2.0 (1.1;2.2) | 1.5 (1.3;3.4) |
| Clinical and laboratory parameters at diagnosis | | | | |
| Blood pressure (mmHg) | 140/85 | 139/88 | 114/53 | 120/66 |
| Symptoms | Fever | Cough | Mild fever and mild cough | Fever and cough |
| SpO2%, room air | 99 | 98 | 97 | 98 |
| CRP (mg/l) | 13.00 | 17.30 | 14.00 | 42.00 |
| LDH U/L | 263 | 234 | 186 | 230 |
| Anti Spike IgG BAU/ml | NA | 1410 | > 2080 | 23.6 |
| Infection duration (days) | 12 | 14 | 12 | 11 |
| Follow-up (days) | 42 | 31 | 30 | 44 |
| Outcome | Infection recovery | Infection recovery | Infection recovery | Infection recovery |

OLHDF online hemodiafiltration, HD hemodialysis, AVF arteriovenous fistula, PM pace maker, CVC central venous catheter, UC ulcerative colitis, DVT deep vein thrombosis, VKA vitamin K antagonist, CRP C-Reactive Protein

Intra-dialysis drug administration provided several advantages. First, it allowed an adequate length of clinical observation during the Dialysis Center stay as described for intradialytic Bamlanivimab/Etesevimab administration [15]. Sotrovimab indeed requires a single intravenous infusion over 30 min and patients should be monitored during administration, and for at least 1 h afterwards. Drug administration during the second hour of the dialysis treatment allowed us to monitor the patients until the end of the dialysis treatment itself. Furthermore, intradialytic administration avoided a further hospital access, thereby limiting the patients’ discomfort.

Second, we avoided the need for patient hospitalization, thus reducing bed occupancy. Third, we avoided having to make an additional trip to the hospital and in so doing, we reduced (a) the risk of infection diffusion, (b) the use of
dedicated transport personnel and means, and (c) the consumption of personal protective equipment, therefore allowing us to decrease the utilization of resources and to lower costs.

The chronic hemodialysis outpatients described above had good outcomes. During Sotrovimab administration they had no clinical complications.

Unfortunately, we have no data concerning the viral load decline. One patient was not tested for anti-spike IgG protein before treatment. According to our Hospital protocol, follow up was performed by nasal swab and we have no data on nasopharyngeal CRP. Data regarding infection and follow up duration are shown in Table 1.

Besides the low number of patients, our experience has another limitation. Hypotension is a complication of dialysis treatment but during Sotrovimab administration it can be both dialysis-dependent and an adverse drug event. Medical history and patients’ usual clinical behavior during dialysis treatment could help to interpret the event. On the other hand, drug administration during dialysis treatment has the advantage of constant monitoring and the possibility of prompt intervention.

Conclusions

In our experience, the administration of Sotrovimab during the intermittent hemodialysis session was well tolerated and no adverse reactions were observed. Intradialytic use allowed adequate observation time without prolonging hospital stay in chronic hemodialysis outpatients.

Our experience suggests that administration of Sotrovimab during dialysis is feasible.

Declarations

Conflict of interest On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

1. Williamson EJ, Walker AJ, Bhaskaran K et al (2020) Factors associated with COVID-19-related death using OpenSAFELY. Nature 584:430–436. https://doi.org/10.1038/s41586-020-2521-4

2. Goffin E, Candelier A, Vart P et al (2021) COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. Nephrol Dial Transplant 36:2094–2105. https://doi.org/10.1093/ndt/gfab200

3. Chen P, Nirula A, Heller B et al (2021) SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. N Engl J Med 384:229–237. https://doi.org/10.1056/NEJMoa2029849

4. Weinreich DM, Sivapalasingam S, Norton T et al (2021) REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N Engl J Med 384:238–251. https://doi.org/10.1056/NEJMoa2035002

5. Pinto D, Park Y-J, Beltramello M et al (2020) Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583:290–295. https://doi.org/10.1038/s41586-020-2349-y

6. Gupta A, Gonzalez-Rojas Y, Juarez E et al (2021) Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody Sotrovimab. N Engl J Med 385:1941–1950. https://doi.org/10.1056/NEJMoa2107934

7. Iketani S, Liu L, Guo Y et al (2022) Antibody evasion properties of SARS-CoV-2 Omicron Sublineages. Nature 604:553–556. https://doi.org/10.1038/s41586-022-04594-4

8. Gottlieb RL, Vaca CE, Paredes R et al (2022) Early Remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med 386:305–315. https://doi.org/10.1056/NEJMoa216846

9. Aiswarya D, Arumugam V, Dineshkumar T et al (2021) Use of Remdesivir in patients With COVID-19 on hemodialysis: a study of safety and tolerance. Kidney Int Rep 6:586–593. https://doi.org/10.1016/j.ekir.2020.12.003

10. Adamsick ML, Gandhi RG, Bidell MR et al (2020) Remdesivir in patients with acute or chronic kidney disease and COVID-19. J Am Soc Nephrol 31:1384–1386. https://doi.org/10.1681/ASN.2020050589

11. Hammond J, Leister-Tebbe H, Gardner A et al (2022) Oral Nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med 386:1397–1408. https://doi.org/10.1056/NEJMoa2118542

12. Hiremath S, McGuinty M, Argyropoulos C et al (2022) Prescribing Nirmatrelvir/Ritonavir (Paxlovid) for COVID-19 in advanced chronic kidney disease. Clin J Am Soc Nephrol CJN. https://doi.org/10.2215/CJN.05270522

13. Brown PA, McGuinty M, Argyropoulos C et al (2022) Early experience with modified dose nirmatrelvir/ritonavir in dialysis patients with coronavirus disease-2019. Nephrology 39(10334):1513

14. http://rr.auslromagna.it/comunicazione/emergenza-covid-19/documenti-covid/epidemiologia/bollettino-covid-19

15. Gasperoni L, Abenavoli C, Donati G et al (2022) Safety of Intradialytic Bamlanivimab/Etesevimab administration in two COVID-19 dialysis outpatients. Blood Purif. https://doi.org/10.1159/000521637

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.